BUY Mankind Pharma — Kavita Jain, 10 Jun 2026

byKavita Jain, Arihant Capital MarketsHorizon: NA (inferred Swing (≤2wk))10 Jun 2026via CNBC Awaaz.

Entry₹2,400Stated

Target₹2,450

Stop loss₹2,360-1.67% risk

Exit₹2,36011 Jun 2026, 9:15 am

Stop-loss hit-1.67%

Follow Kavita Jain for new calls(48% target hit, 54 closed calls)Get alerts Watch MANKIND for new buy/sell callsGet alerts See 1 active Swing call on MANKIND See 182 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 8 Sept, 5:13 pm IST

3 supporting0 opposing

Supports the BUY call (3)

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·3 Jun · 1w ago

Mankind Pharma Limited, through its subsidiary, acquired the remaining 10% stake in Upakarma Ayurveda Private Limited, making Upakarma a wholly-owned subsidiary. This acquisition aims to improve opera

NSE · Acquisition·2 Jun · 1w ago

Mankind Pharma Ltd has informed about a stake acquisition by one of its wholly-owned subsidiary companies.

BSE · Company Update·2 Jun · 1w ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

BUY Mankind Pharma Limited — Kavita Jain, Arihant Capital Markets

AI Assessment